Vifor: VFMCRP receives EU approval for Tavneos for the treatment of ANCA-associated vasculitis
First orally administered therapy for the treatment of the two main types of ANCA-associated vasculitis approved in Europe First launches expected in H1 2022 Regulatory News: Vifor Fresenius
Source: finanznachrichten.de